Does the media refer more to ARDX or GPCR?

In the previous week, Ardelyx had 12 more articles in the media than Structure Therapeutics. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.03 beat Ardelyx's score of 0.16 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Structure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ARDX or OGN?

Organon & Co. has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $450.89M 2.15 -$61.60M -$0.22 N/A Organon & Co. $6.22B 0.58 $187M $0.77 17.87

Is ARDX or OGN more profitable?

Organon & Co. has a net margin of 3.41% compared to Ardelyx's net margin of -12.35%. Organon & Co.'s return on equity of 88.97% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% Organon & Co. 3.41% 88.97% 6.03%

Does the media refer more to ARDX or OGN?

In the previous week, Ardelyx had 13 more articles in the media than Organon & Co.. MarketBeat recorded 15 mentions for Ardelyx and 2 mentions for Organon & Co.. Ardelyx's average media sentiment score of 0.16 beat Organon & Co.'s score of 0.14 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ARDX or MBX more profitable?

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -12.35% -36.00% -10.77% MBX Biosciences N/A -26.02% -24.94%

Does the media favor ARDX or MBX?

In the previous week, Ardelyx had 10 more articles in the media than MBX Biosciences. MarketBeat recorded 15 mentions for Ardelyx and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.25 beat Ardelyx's score of 0.16 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARDX or ARQT?

In the previous week, Ardelyx had 11 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 15 mentions for Ardelyx and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.84 beat Ardelyx's score of 0.16 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$3.89 -0.01 (-0.26%)

As of 08/21/2026 04:00 PM Eastern

Compare

ARDX vs. CPRX, GPCR, OGN, MBX, and ARQT

Should you buy Ardelyx stock or one of its competitors? Ardelyx's main competitors and comparable companies include Catalyst Pharmaceuticals (CPRX), Structure Therapeutics (GPCR), Organon & Co. (OGN), MBX Biosciences (MBX), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ardelyx compare to Catalyst Pharmaceuticals?

Ardelyx (NASDAQ:ARDX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Ardelyx had 15 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 15 mentions for Ardelyx and 0 mentions for Catalyst Pharmaceuticals. Ardelyx's average media sentiment score of 0.16 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Neutral
Catalyst Pharmaceuticals	Neutral

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ardelyx presently has a consensus price target of $13.90, suggesting a potential upside of 257.33%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 1.62%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Ardelyx's net margin of -12.35%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Ardelyx has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Summary

Catalyst Pharmaceuticals beats Ardelyx on 12 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Structure Therapeutics?

Ardelyx (NASDAQ:ARDX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ardelyx had 12 more articles in the media than Structure Therapeutics. MarketBeat recorded 15 mentions for Ardelyx and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.03 beat Ardelyx's score of 0.16 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Structure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, indicating that its share price is 243% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Structure Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Structure Therapeutics' return on equity of -25.56% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Structure Therapeutics	N/A	-25.56%	-24.31%

Ardelyx presently has a consensus target price of $13.90, suggesting a potential upside of 257.33%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 125.93%. Given Ardelyx's higher probable upside, research analysts plainly believe Ardelyx is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Ardelyx and Structure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Organon & Co.?

Ardelyx (NASDAQ:ARDX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Organon & Co. has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.87

In the previous week, Ardelyx had 13 more articles in the media than Organon & Co.. MarketBeat recorded 15 mentions for Ardelyx and 2 mentions for Organon & Co.. Ardelyx's average media sentiment score of 0.16 beat Organon & Co.'s score of 0.14 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Ardelyx's net margin of -12.35%. Organon & Co.'s return on equity of 88.97% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Organon & Co.	3.41%	88.97%	6.03%

Ardelyx presently has a consensus target price of $13.90, suggesting a potential upside of 257.33%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.15%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Summary

Organon & Co. beats Ardelyx on 9 of the 17 factors compared between the two stocks.

How does Ardelyx compare to MBX Biosciences?

Ardelyx (NASDAQ:ARDX) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. MBX Biosciences' return on equity of -26.02% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
MBX Biosciences	N/A	-26.02%	-24.94%

58.9% of Ardelyx shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ardelyx has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Ardelyx had 10 more articles in the media than MBX Biosciences. MarketBeat recorded 15 mentions for Ardelyx and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.25 beat Ardelyx's score of 0.16 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx currently has a consensus price target of $13.90, indicating a potential upside of 257.33%. MBX Biosciences has a consensus price target of $77.00, indicating a potential upside of 16.09%. Given Ardelyx's higher possible upside, research analysts clearly believe Ardelyx is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Summary

Ardelyx beats MBX Biosciences on 9 of the 15 factors compared between the two stocks.

How does Ardelyx compare to Arcutis Biotherapeutics?

Ardelyx (NASDAQ:ARDX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Arcutis Biotherapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.15	-$61.60M	-$0.22	N/A
Arcutis Biotherapeutics	$376.07M	8.38	-$16.14M	$0.21	119.43

In the previous week, Ardelyx had 11 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 15 mentions for Ardelyx and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.84 beat Ardelyx's score of 0.16 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a net margin of 6.15% compared to Ardelyx's net margin of -12.35%. Arcutis Biotherapeutics' return on equity of 15.05% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Ardelyx has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Ardelyx presently has a consensus price target of $13.90, suggesting a potential upside of 257.33%. Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 41.83%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts plainly believe Ardelyx is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

58.9% of Ardelyx shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Ardelyx on 10 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$969.34M	$12.57B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-17.68	789.80	272.60	24.24
Price / Sales	2.15	764.50	618.96	99.78
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	6.48	11.89	13.05	6.20
Net Income	-$61.60M	$2.81B	$3.47B	$348.59M
7 Day Performance	-4.19%	1.77%	2.09%	0.08%
1 Month Performance	-24.17%	3.85%	6.64%	3.88%
1 Year Performance	-36.33%	6.56%	25.02%	16.98%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	3.0279 of 5 stars	$3.89 -0.3%	$13.90 +257.3%	-36.3%	$969.34M	$450.89M	N/A	90	Analyst Forecast
CPRX Catalyst Pharmaceuticals	2.8783 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80
GPCR Structure Therapeutics	2.4942 of 5 stars	$53.76 -1.4%	$110.91 +106.3%	+150.3%	$3.80B	N/A	N/A	136	Positive News
OGN Organon & Co.	1.1717 of 5 stars	$13.70 -0.1%	$11.40 -16.8%	+46.1%	$3.60B	$6.22B	17.79	10,000
MBX MBX Biosciences	2.9855 of 5 stars	$68.25 -0.5%	$75.63 +10.8%	N/A	$3.30B	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. CPRX, GPCR, OGN, MBX, and ARQT

How does Ardelyx compare to Catalyst Pharmaceuticals?

Summary

How does Ardelyx compare to Structure Therapeutics?

Summary

How does Ardelyx compare to Organon & Co.?

Summary

How does Ardelyx compare to MBX Biosciences?

Summary

How does Ardelyx compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. CPRX, GPCR, OGN, MBX, and ARQT

How does Ardelyx compare to Catalyst Pharmaceuticals?

Does the media favor ARDX or CPRX?

Do institutionals and insiders have more ownership in ARDX or CPRX?

Do analysts prefer ARDX or CPRX?

Is ARDX or CPRX more profitable?

Which has more risk & volatility, ARDX or CPRX?

Which has stronger earnings & valuation, ARDX or CPRX?

Summary

How does Ardelyx compare to Structure Therapeutics?

Do insiders and institutionals hold more shares of ARDX or GPCR?

Does the media refer more to ARDX or GPCR?

Which has more risk & volatility, ARDX or GPCR?

Which has better earnings & valuation, ARDX or GPCR?

Is ARDX or GPCR more profitable?

Do analysts rate ARDX or GPCR?

Summary

How does Ardelyx compare to Organon & Co.?

Which has better earnings & valuation, ARDX or OGN?

Does the media refer more to ARDX or OGN?

Do insiders and institutionals hold more shares of ARDX or OGN?

Is ARDX or OGN more profitable?

Do analysts rate ARDX or OGN?

Which has more risk & volatility, ARDX or OGN?

Summary

How does Ardelyx compare to MBX Biosciences?

Is ARDX or MBX more profitable?

Do institutionals and insiders believe in ARDX or MBX?

Which has better valuation and earnings, ARDX or MBX?

Does the media favor ARDX or MBX?

Do analysts rate ARDX or MBX?

Which has more risk and volatility, ARDX or MBX?

Summary

How does Ardelyx compare to Arcutis Biotherapeutics?

Which has stronger valuation & earnings, ARDX or ARQT?

Does the media refer more to ARDX or ARQT?

Is ARDX or ARQT more profitable?

Which has more risk and volatility, ARDX or ARQT?

Do analysts prefer ARDX or ARQT?

Do institutionals & insiders hold more shares of ARDX or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools